INS and Hypoglycemia: This suggests a more favorable tolerability profile in our real-world population, possibly due to gradual dose titration or differences in patient characteristics. Notably, 24% of patients experienced hypoglycemia, likely due to the concurrent use of insulin or sulfonylureas, which are known to increase the risk of low blood glucose when combined with GLP-1 receptor agonists [21].